Research programme: cannabinoid therapeutics- GB Sciences

Drug Profile

Research programme: cannabinoid therapeutics- GB Sciences

Alternative Names: BCTC - Makai Biotechnology; TRPV1 inhibitors

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Hawaii
  • Developer GB Sciences; Makai Biotechnology
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Immunomodulators; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Heart failure; Inflammation; Neuropathic pain

Most Recent Events

  • 17 Oct 2017 GB Sciences in-licenses intellectual property covering time-released formulation of cannabinoid from from the Universidad de Sevilla, the Universidad de Cadiz and the Centro de Investigación Biomédica en Red de Salud Mental
  • 26 Jul 2017 Preclinical trials in Neuropathic pain in USA (PO)
  • 26 Jul 2017 Pharmacodynamics data from a preclinical trial in Neuropathic pain released by Universidad de Seville, the Universidad de Cadiz and the Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top